Acute Cardiovascular Events Triggered by COVID-19-Related Stress

NCT ID: NCT04368637

Last Updated: 2020-05-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

50 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-05-03

Study Completion Date

2020-08-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The current COVID19 pandemic has afflicted almost the whole globe. The stress related to the pandemic, not the direct virus-related injury, can be potentially associated with acute cardiovascular events due to a large list of physical and psychosocial stresses.

This study is a cross sectional study that will enroll patients evaluated during the COVID19 pandemic period for acute cardiovascular events.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The onset of acute myocardial infarction (AMI) is a complex interplay of internal circadian factors and external physical and emotional triggers. These interactions may lead to rupture of an often non-occlusive vulnerable atherosclerotic coronary plaque with subsequent formation of an occlusive thrombus. Physical and emotional stresses are important triggers of acute cardiovascular events including AMI. Triggering events, internal changes, and external factors vary among different geographical, environmental, and ethnic regions. Life-style changes, pharmacotherapy, and psychological interventions may potentially modify the response to, and protect against the effects of triggering events. Certain times in the life span of different communities all around the world are prone to natural and man-made disasters that, not only have direct negative impact on human lives and state-resources, but also have indirect impact on triggering acute cardiovascular events during the time of the disaster and the period immediately after. For example, earthquakes, wars, and terrorist attacks, in addition to direct human life loss and destruction of communities, have bees associated with a surge in the number of acute MI, sudden cardiac death, ventricular tachy-arrhythmia and implantable cardiovertor defibrillators (ICD) discharges.

The current COVID-19 pandemic has afflicted almost the whole globe. The virus can directly attack the myocyte and cause various degrees of cardiac damage and cardiovascular clinical entities. However, the stress related to the pandemic, not the direct virus-related injury, can be potentially associated with acute cardiovascular events due to a large list of physical and psycho-social stresses such as extreme physical effort, lock down, anger, fear, financial stress, sorrow, death of a significant person..etc.

This study is a cross sectional study that will enroll patients evaluated during the COVID-19 pandemic period for acute cardiovascular events not directory related to the virus infectivity, who voice certain and specific trigger(s) related to the pandemic impact on social life and physical activity.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Myocardial Infarction Ventricular Tachycardia Sudden Cardiac Death Stroke, Acute

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age \>18 years.
* Acute MI (STEMI and NSTEMI).
* Sudden cardiac death
* Ventricular tachycardia
* ICD shocks.
* Stressful trigger prior to the cardiovascular event

Exclusion Criteria

\* COVID-19 infection.
Minimum Eligible Age

18 Years

Maximum Eligible Age

100 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Jordan Collaborating Cardiology Group

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Ayman J. Hammoudeh, MD, FACC

Interventional Cardiologist

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ayman J Hammoudeh, MD, FACC

Role: STUDY_CHAIR

JCC Group

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Istishari Hospital

Amman, , Jordan

Site Status RECRUITING

Abdelhadi Hospital

Amman, , Jordan

Site Status RECRUITING

Farah Hospital

Amman, , Jordan

Site Status RECRUITING

Jordan Hospital

Amman, , Jordan

Site Status RECRUITING

Specialty Hospital

Amman, , Jordan

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Jordan

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Ayman J Hammoudeh, MD, FACC

Role: CONTACT

0096265001000

Ayadeh Madanat, MD

Role: CONTACT

00962796224241

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Ayman Hammoudeh, MD, FACC

Role: primary

0096265001000

Walaa Abu Moghli, PharmD

Role: backup

0096265001000

Zeina Abu Orabi, MD

Role: primary

Hadi Abu hantash, MD, FACC

Role: primary

Imad Alhaddad, MD

Role: primary

00962795303502

Mahmoud Izraiq Mahmoud Izraiq, MD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

JCCG.JoCORE.4.4040

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Adrecizumab in Cardiogenic Shock
NCT03989531 COMPLETED PHASE2/PHASE3